Immediate Impact

7 standout
Sub-graph 1 of 3

Citing Papers

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
2023 Standout
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2023 Standout
2 intermediate papers

Works of É. Lagneau being referenced

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
2019
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study
2018

Author Peers

Author Last Decade Papers Cites
É. Lagneau 156 7 27 212 160 15 376
Lucianna Sparano 73 15 216 119 13 389
H Tobon 63 57 172 48 15 367
Dvora Cyrlak 68 50 161 76 13 336
Stavros N Georgiannos 144 21 99 62 13 412
Edward J. Tabah 179 2 7 138 41 11 377
Alisa C. Thorne 31 6 17 110 46 14 350
Maria Grazia Cattani 32 28 246 142 13 363
Erjiang Tang 111 1 19 140 37 22 352
Fatma Paksoy Türköz 133 1 20 81 37 19 450
Michael L. Palmer 118 20 112 39 17 446

All Works

Loading papers...

Rankless by CCL
2026